Módulo 1 – Curso pós-graduado – VIH e Envelhecimento

Drug-drug Interactions and Polypharmacy in Older HIV Persons

Polymedication and drug metabolism in aging patients

Bibliografia

  1. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120-6.
  2. Guaraldi 2012. Conceptual approaches for defining frailty phenotype in HIV. 3rd International Workshop on HIV & Aging. 2012 (disponível em http://regist2. virology-education.com/2012/3HIVaging/docs/33_Guaraldi.pdf, acedido em 2015-07-14)
  3. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011;66(9):2107-11.
  4. Reyataz – Summary of Product Characteristics, 2012
  5. Norvasc – Summary of Product Characteristics, 2012
  6. Singh GJ, Jackson A, D’Avolio A, et al. No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals AIDS 2014;28(13):1993-5
  7. Zong J, Borland J, Jerva F, et al. The effect of dolutegravir on the pharma- cokinetics of metformin in healthy subjects. J Int AIDS Soc. 2014;17(4 Suppl 3):19584.
  8. German P, Garrison K, Pang PS, et al. Drug-drug interactions between anti-HCV regimen ledipasvir/sofosbuvir and antiretrovirals. CROI February 23-26, 2015, Seattle, Washington (abstract disponível em http://www.croiconference.org/ sessions/drug-drug-interactions-between-anti-hcv-regimen-ledipasvirsofosbuvir-and-antiretrovirals, acedido em 2015-07-14)
  9. Cevik M, Dickinson L, Ahmed A, et al. Tenofovir (TFV) pharmacokinetics (PK) in HIV infected individuals over 40 years of age, abstr PS6/1. 13th Eur. AIDS Clin. Soc. Conf., 2011 Belgrade, Serbia
  10. Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013;68(6):1354-9.
  11. Vera JH, Jackson A, Dickinson L, et al. The pharmacokinetic profile of raltegra- vir-containing antiretroviral therapy in HIV-infected individuals over 60years of age. HIV Clin Trials. 2015;16(1):39-42.
  12. A prospective, observational study to examine the effects of ageing on the ‘pharmacokinetic and clinical observations in people over fifty’ (POPPY). (disponível em https://clinicaltrials.gov/ct2/show/NCT01737047 acedido em 2015-07-14)
  13. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15(1):1-5.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018